Biotechnology major Moderna on Friday sued rival Pfizer and BioNTech over alleged infringement of its messenger RNA (mRNA) vaccine technology patents.
More than half of those earnings will be off of its two Covid products, with the vaccine expected to bring in $32 billion in sales, and Paxlovid expected to earn $22 billion.
The trials would evaluate the safety, tolerability and immunogenicity of the vaccine candidate, according to a joint statement by the companies on Tuesday. The study would involve up to 1,420 participants.
COVID19 Third Wave Is Here’ | Top COVID, OMICRON Headlines
The pill has also been approved for those at high risk for progression to severe Covid-19, including hospitalisation or death.
Pfizer also released early data from a second clinical trial showing that the treatment reduced hospitalisations by around 70 per cent in around 600 standard-risk adults.
In addition, a significantly higher number of short-lived vaccine reactions were reported in volunteers who received a second dose of Moderna compared to those who received two doses of either AstraZeneca or Pfizer.
Moderna requested authorisation of its 50 microgram booster dose for all adults on Wednesday. The company said the FDA based the emergency use authorisation (EUA) on the "totality of scientific evidence shared by the company," including data that showed neutralizing antibodies had waned at about six months.
Pfizer will not receive royalties on sales in low-income countries and will further waive royalties on sales in all countries covered by the agreement while Covid-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.
"The vaccine is one-third the adult dose and the vaccine would be given in two doses, three weeks apart. "
Facebook will also remove any claim that Covid-19 vaccines can kill or seriously harm kids, that they are not effective for children at all, and that anything other than a Covid-19 vaccine can inoculate children against the virus.
"Covid-19 is "the eighth-highest killer of kids in this age group over the past year,"
If authorised, Pfizer-BioNTech vaccine would be the first Covid-19 vaccine for younger children.
New York: US-based pharmaceutical major Pfizer’s Chief Executive Officer Albert Bourla said that the company’s Covid-19 oral antiviral pill, which is in early-stage trials, could be ready by the end…
New Delhi: US pharma major Pfizer on Thursday offered to supply the Pfizer-BioNTech vaccine at a “not-for-profit” price, media reports have cited. The company had earlier said that it will…